Payment overview · 2025
General Payments
$355.03
18 reported records · 9 companies
Healthcare provider profile · identity verified
Stephen D Fillman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHENANDOAH, TX · NPI 1992779961
Verified facts
What the public records show
CMS Open Payments records show Stephen D Fillman, MD received $355.03 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Synthroid, Teriparatide.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.19 | 20.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.96 | 20.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.98 | 11.8% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $37.25 | 10.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.72 | 9.8% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.96 | 8.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.93 | 7.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $22.76 | 6.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.28 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.03 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.58 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $37.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 217 | exact normalized | Medicare Part D |
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
217 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1182 | 320 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1161 | 339 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 149 |
| Ezetimibe | Ezetimibe | 386 | 126 |
| Sertraline Hcl | Sertraline Hcl | 329 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 98 |
| Montelukast Sodium | Montelukast Sodium | 290 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 84 |
| Metformin Hcl Er | Metformin Hcl | 276 | 79 |
| Valsartan | Valsartan | 273 | 75 |
| Trazodone Hcl | Trazodone Hcl | 259 | 65 |
| Gabapentin | Gabapentin | 242 | 60 |
| Omeprazole | Omeprazole | 238 | 73 |
| Synthroid | Levothyroxine Sodium | 217 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 68 |
| Losartan Potassium | Losartan Potassium | 199 | 60 |
| Metformin Hcl | Metformin Hcl | 191 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 180 | 54 |
| Allopurinol | Allopurinol | 179 | 47 |
| Spironolactone | Spironolactone | 179 | 53 |
| Lisinopril | Lisinopril | 175 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 43 |
| Ozempic | Semaglutide | 161 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 40 |
| Bupropion Xl | Bupropion Hcl | 145 | 44 |
| Alprazolam | Alprazolam | 142 | 35 |
| Alendronate Sodium | Alendronate Sodium | 138 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 39 |
| Carvedilol | Carvedilol | 128 | 34 |
| Irbesartan | Irbesartan | 127 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 51 |
| Tramadol Hcl | Tramadol Hcl | 119 | 30 |
| Famotidine | Famotidine | 110 | 38 |
| Buspirone Hcl | Buspirone Hcl | 109 | 30 |
| Minoxidil | Minoxidil | 109 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 104 | 30 |
| Lorazepam | Lorazepam | 101 | 22 |
| Furosemide | Furosemide | 99 | 43 |
| Jardiance | Empagliflozin | 94 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 23 |
| Prednisone | Prednisone | 85 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 22 |
| Estradiol | Estradiol | 83 | 27 |
| Pregabalin | Pregabalin | 83 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 12 |
| Clonazepam | Clonazepam | 77 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 28 |
| Simvastatin | Simvastatin | 77 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 76 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 66 | 18 |
| Potassium Chloride | Potassium Chloride | 65 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 21 |
| Methylphenidate Hcl | Methylphenidate Hcl | 62 | 18 |
| Meloxicam | Meloxicam | 60 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 58 | 12 |
| Finasteride | Finasteride | 57 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 47 |
| Calcitriol | Calcitriol | 55 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 50 | 13 |
| Fenofibrate | Fenofibrate | 50 | 16 |
| Hydrocortisone | Hydrocortisone | 50 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Nifedipine Er | Nifedipine | 48 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | 17 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 15 |
| Ondansetron Odt | Ondansetron | 45 | 20 |
| Torsemide | Torsemide | 45 | 14 |
| Primidone | Primidone | 44 | 13 |
| Methylprednisolone | Methylprednisolone | 43 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 14 |
| Eliquis | Apixaban | 42 | 17 |
| Rybelsus | Semaglutide | 41 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 40 | suppressed |
| Eszopiclone | Eszopiclone | 40 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | 11 |
| Temazepam | Temazepam | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 15 |
| Gemtesa | Vibegron | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 34 | 11 |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 32 | 12 |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Testosterone | Testosterone | 30 | suppressed |
| Teriparatide | Teriparatide | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 20 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.03 · 18 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Korlym, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, SKYRIZI, SYNTHROID, TERIPARATIDE, Tlando, UBRELVY, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error